We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: HER2
MedXY News
EnglishTag

HER2

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma: Promising Efficacy Across HER2 Expression Levels
newsHER2Antibody-drug conjugate

Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma: Promising Efficacy Across HER2 Expression Levels

By MedXY|Aug 14, 2026

This phase II trial demonstrates significant antitumor activity of trastuzumab rezetecan in both HER2-high and HER2-low advanced salivary gland carcinoma with a manageable safety profile, offering new hope for this challenging malignancy.

Revisiting HER2 Status in Recurrent Cervical Cancer: Clinical Implications of Dynamic Expression for Targeted Therapy
newsrecurrenceHER2

Revisiting HER2 Status in Recurrent Cervical Cancer: Clinical Implications of Dynamic Expression for Targeted Therapy

By MedXY|Aug 18, 2026

HER2 expression in recurrent cervical cancer varies notably by histology and recurrence site, underscoring the importance of reassessment to guide HER2-targeted treatments effectively.

Mapping the Escape: How Spatial Transcriptomics Reveals the Complex Resistance Landscape in HER2-Positive Gastric Cancer
GastroenterologyGastric CancerHER2

Mapping the Escape: How Spatial Transcriptomics Reveals the Complex Resistance Landscape in HER2-Positive Gastric Cancer

By MedXY|Mar 18, 2026

Researchers utilized spatial transcriptomics to uncover how HER2-positive gastric cancers evolve resistance to trastuzumab and T-DXd, identifying EMT, ERAD pathways, and metabolic shifts as key survival mechanisms that could inform future s

HER2-Positivity in Advanced Biliary Tract Cancer: A Dual Role as a Negative Prognostic Factor and a Potent Therapeutic Vulnerability
GastroenterologyBiliary tract cancerHER2

HER2-Positivity in Advanced Biliary Tract Cancer: A Dual Role as a Negative Prognostic Factor and a Potent Therapeutic Vulnerability

By MedXY|Jan 13, 2026

A multi-institutional analysis reveals that HER2-positivity in advanced biliary tract cancer signals a poorer prognosis but offers a significant survival benefit when targeted with anti-HER2 therapies, advocating for routine screening and s

Zanidatamab-Based Triplet Therapy Redefines Survival Expectations in HER2-Positive Gastric Cancer: Insights from a Phase 1b/2 Study
GastroenterologyGastric CancerHER2

Zanidatamab-Based Triplet Therapy Redefines Survival Expectations in HER2-Positive Gastric Cancer: Insights from a Phase 1b/2 Study

By MedXY|Jan 12, 2026

A phase 1b/2 trial reveals that combining the bispecific antibody zanidatamab with tislelizumab and chemotherapy yields a 75.8% response rate and an impressive median overall survival of 32.4 months in first-line HER2-positive gastric and g

Zanidatamab Shows Durable Activity and Pain Benefit in HER2‑Positive Metastatic Biliary Tract Cancer: Final HERIZON‑BTC‑01 Results
newsBiliary tract cancerHER2

Zanidatamab Shows Durable Activity and Pain Benefit in HER2‑Positive Metastatic Biliary Tract Cancer: Final HERIZON‑BTC‑01 Results

By MedXY|Nov 24, 2025

Final HERIZON‑BTC‑01 data show zanidatamab induces durable responses and a median overall survival of 15.5 months in previously treated HER2‑overexpressing metastatic biliary tract cancer, with greatest benefit in IHC 3+ tumors and manageab

Antibody–Drug Conjugates and Heart Risk in HER2-Positive Advanced Breast Cancer: What Clinicians Need to Know
Cardiologyantibody-drug conjugatesCardio-Oncology

Antibody–Drug Conjugates and Heart Risk in HER2-Positive Advanced Breast Cancer: What Clinicians Need to Know

By MedXY|Nov 19, 2025

A 2025 meta-analysis of 9,538 patients found trastuzumab emtansine (T‑DM1) carries the lowest incidence of LVEF decline (0.94%), while trastuzumab deruxtecan (T‑DXd) and trastuzumab-based combinations show similar, modest rates (≈4–5%). Tri

Innovative Immunotherapy Combines to Transform Treatment of HER2-Expressing Advanced Urothelial Cancer
OncologyHER2immunotherapy

Innovative Immunotherapy Combines to Transform Treatment of HER2-Expressing Advanced Urothelial Cancer

By MedXY|Oct 24, 2025

This study demonstrates that disitamab vedotin plus toripalimab significantly improves survival outcomes over chemotherapy in untreated HER2-positive advanced urothelial cancer.

Prognostic Role of HER2 Amplification and Mutations in Metastatic Colorectal Cancer: Insights from Eight Randomized Trials
Clinical Updatesanti-EGFRbevacizumab

Prognostic Role of HER2 Amplification and Mutations in Metastatic Colorectal Cancer: Insights from Eight Randomized Trials

By MedXY|Oct 7, 2025

HER2 amplification/mutation in RAS/BRAF wild-type metastatic colorectal cancer is a negative prognostic factor but does not predict differential benefit from bevacizumab or anti-EGFR therapies, based on analysis of 1,604 patients across eig

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities